Tremelimumab
Showing 1 - 25 of 219
Mesothelioma Trial in Durham, Houston (Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemo plus
Not yet recruiting
- Mesothelioma
- Durvalumab / tremelimumab
- Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
-
Durham, North Carolina
- +1 more
Jul 5, 2023
BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Trial in Bobigny (Durvalumab/Tremelimumab in neoadjuvant
Not yet recruiting
- BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA
- Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
-
Bobigny, FranceHospitl Avicenne
Sep 13, 2023
Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)
Not yet recruiting
- Borderline Resectable Carcinoma
- Biliary Tract Cancer
- Durvalumab
- +4 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023
Unrescetable Hepatocellular Carcinoma Trial in Tianjin (HAIC+Durvalumab+Tremelimumab+Bevacizumab)
Not yet recruiting
- Unrescetable Hepatocellular Carcinoma
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital Airport Hospital
May 16, 2023
Hepatocellular Carcinoma Trial in Munich, Würzburg (durvalumab, tremelimumab, bevacizumab)
Recruiting
- Hepatocellular Carcinoma
- durvalumab, tremelimumab, bevacizumab
-
Munich, Germany
- +2 more
May 3, 2023
Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma Trial in Hannover (Durvalumab and Tremelimumab,
Completed
- Metastatic Adult Soft Tissue Sarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Durvalumab and Tremelimumab
- Doxorubicin
-
Hannover, GermanyMedizinische Hochschule Hannover
Jan 18, 2023
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer Trial in Boston (Durvalumab, Tremelimumab,
Not yet recruiting
- Resectable Hepatocellular Carcinoma
- +2 more
- Durvalumab
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 18, 2023
NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab
- +5 more
- (no location specified)
Aug 17, 2023
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC) Trial in Philadelphia (Radiotherapy, MEDI4736, Tremelimumab)
Active, not recruiting
- Metastatic
- +4 more
- Radiotherapy
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jan 6, 2023
Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)
Not yet recruiting
- Hepatocellular Carcinoma
- Durvalumab
- Tremelimumab
- (no location specified)
Sep 27, 2022
Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma Trial in Baltimore (Durvalumab, Tremelimumab (Cohort A
Recruiting
- Intermediate Stage of Hepatocellular Carcinoma
- Hepatocellular Carcinoma
- Durvalumab
- +2 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Oct 6, 2022
Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial run by the NCI (durvalumab,
Recruiting
- Hepatocellular Cancer
- +2 more
- durvalumab
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma Trial in Worldwide (Tremelimumab
Active, not recruiting
- Urothelial Bladder Cancer
- +2 more
- Tremelimumab monotherapy
- +2 more
-
San Francisco, California
- +13 more
Jan 20, 2023
Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic
Not yet recruiting
- Locally Advanced Intrahepatic Cholangiocarcinoma
- +4 more
- Angiography
- +8 more
-
Jacksonville, FloridaMayo Clinic in Florida
Sep 22, 2023
Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer Trial in Edmonton (Durvalumab, Gemcitabine, Nab paclitaxel)
Not yet recruiting
- Pancreatic Cancer
- +3 more
- Durvalumab
- +5 more
-
Edmonton, Alberta, CanadaCross Cancer Institute
Feb 1, 2023
Metastatic Breast Cancer Trial in New York (Brain radiotherapy or Stereotactic Radiosurgery, Tremelimumab, HER2 directed
Completed
- Metastatic Breast Cancer
- Brain radiotherapy or Stereotactic Radiosurgery
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Aug 2, 2022
Unresectable Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)
Available
- Unresectable Hepatocellular Carcinoma
- Durvalumab
- Tremelimumab
- (no location specified)
Aug 12, 2022
Hepatocellular Carcinoma Trial in Chicago, New York (TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi)
Recruiting
- Hepatocellular Carcinoma
- TheraSphere Y-90 glass microsphere therapy
- +2 more
-
Washington, District of Columbia
- +7 more
Jan 17, 2023
Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,
Terminated
- Recurrent Gynecological Cancer
- +10 more
- Durvalumab
- +2 more
-
Boston, MassachusettsMartin King
Oct 4, 2022
Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7 Trial in Houston (biological, other,
Completed
- Metastatic Carcinoma in the Liver
- +4 more
- Durvalumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023
Gastric Cancer, Microsatellite Instability Trial in Milan (Durvalumab, Tremelimumab)
Recruiting
- Gastric Cancer
- Microsatellite Instability
- Durvalumab
- Tremelimumab
-
Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori di Milano
Aug 3, 2022
Cholangiocarcinoma Trial in Birmingham (Novel combination of chemo and immunotherapy)
Recruiting
- Cholangiocarcinoma
- Novel combination of chemotherapy and immunotherapy
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Jul 28, 2022
Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma Trial in United States (Durvalumab, Tremelimumab)
Completed
- Endometrial Cancer
- +4 more
- Durvalumab
- Tremelimumab
-
Basking Ridge, New Jersey
- +6 more
Jan 3, 2023
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer AJCC v7 Trial in Houston (procedure,
Completed
- Clear Cell Renal Cell Carcinoma
- +2 more
- Cryosurgery
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 6, 2022